A NeuroTech startup dedicated to helping people regulate stress and unlock peak performance has raised £850,000 in pre-seed funding.
This investment will support the launch of MindSpire’s first device, SONA, a medical-grade wearable that delivers precision-coded electrical pulses to the vagus nerve, activating brain circuits for calm, focus and enhanced learning.
It is also supported by early clinical studies for the treatment of stress, tinnitus, Parkinson’s Disease and chronic pain.
The round was led by SFC Capital, with participation from SyndicateRoom and non-dilutive innovation funding secured via Innovate UK’s Investor Partnership Programme.
The Kent-based firm is looking to make advanced nervous system care more effective for high performers and meaningful for those who need it most.
Early sales of its flagship device will continue to fund research into how the technology can relieve chronic stress in people facing real-world challenges such as anxiety, long COVID, trauma, burnout and frontline fatigue.
“Our goal is to create a solution that performs just as well for executives managing stress and recovery as it does for individuals rebuilding from chronic conditions,” said Jane Ollis, CEO and founder, MindSpire.
“It reflects our commitment to making nervous system care accessible, especially for those who need it most.”
Tom Britton, founding partner, SyndicateRoom, added: “We’re delighted to invest in MindSpire and enable them complete the development and launch of SONA.
“We look forward to the impact they make in treating chronic stress and anxiety, and to welcome another promising company at the cross section of AI and cutting edge healthtech to the Access EIS portfolio.”